2020
A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)
Hark S, Jamain S, Schijven D, Lin B, Bakker M, Boland-Auge A, Deleuze J, Troudet R, Malhotra A, Gülöksüz S, Vinkers C, Ebdrup B, Kahn R, Leboyer M, Luykx J. A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). Journal Of Psychopharmacology 2020, 34: 524-531. PMID: 32126890, PMCID: PMC7222287, DOI: 10.1177/0269881120907972.Peer-Reviewed Original Research
2019
Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)
Pandit R, Cianci D, Hark S, Rossum I, Ebdrup B, Broberg B, Garcia‐Portilla M, Bobes J, Vinkers C, Kahn R, Guloksuz S, Huitema A, Luykx J. Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatrica Scandinavica 2019, 140: 283-290. PMID: 31323113, PMCID: PMC6771865, DOI: 10.1111/acps.13074.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis patientsPsychosis patientsWeight gainSchizophreniform disorderAntipsychotic-induced weight gainFirst-episode patientsManagement of schizophreniaLower baseline weightMultivariable regression modelsWeight-reducing strategiesOptimization of treatmentRegression modelsMajor depression disorderPhenotypic factorsAmisulpride treatmentBaseline weightEurope (Syst-Eur) trialMost antipsychoticsDepression disorderYoung subjectsBody weightPatientsBetter efficacyYounger ageAIWG